Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (symbol: SNDX) is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. Dedicated to the development of combination therapies, the company primarily focuses on innovative treatments for various cancer indications.
Syndax's pipeline is rich with promising drugs aimed at improving the lives of cancer patients. The company's leading candidates include entinostat, an agent that targets both cancer cells and immune regulatory cells, and revumenib, a selective inhibitor of the menin-KMT2A binding interaction. This agent is particularly geared towards addressing acute leukemias such as KMT2A-rearranged (KMT2Ar) and NPM1-mutant acute myeloid leukemia (AML). Another notable product in development is axatilimab, a monoclonal antibody designed to enhance the immune response against tumors through CSF-1R inhibition.
Syndax operates primarily within the United States and has achieved several milestones. Recently, the company completed enrollment in the pivotal AUGMENT-101 trial for revumenib targeting relapsed/refractory mutant nucleophosmin (mNPM1) AML. The trial aims to evaluate revumenib's safety, tolerability, and efficacy, with topline data expected by the end of 2024. Positive results from this trial could support new drug applications in early 2025.
Revumenib has achieved several regulatory designations, including Orphan Drug, Fast Track, and Breakthrough Therapy by the FDA, reflecting its potential to address unmet clinical needs in leukemias. Syndax has also reported encouraging outcomes from its studies, including high response rates and favorable safety profiles in both adult and pediatric populations suffering from acute leukemia.
Financially, Syndax maintains a robust position to advance its clinical programs. The company regularly updates stakeholders through earnings calls and investor presentations, with a recent update scheduled for May 2024. Syndax's progress is further bolstered by strategic partnerships and collaborations that support its mission to innovate and deliver significant value to patients and shareholders alike.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Keith A. Goldan as Chief Financial Officer. Goldan, with nearly 30 years of experience in the pharmaceutical sector, previously served as CFO at Optinose, assisting in the launch of XHANCE. CEO Michael A. Metzger emphasized Goldan's expertise as crucial for the company's growth. The press release also highlighted upcoming pivotal readouts for revumenib and axatilimab, both targeting significant cancer treatment needs. Additionally, Sharon Klahre was appointed Vice President of Investor Relations.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced participation in two investor conferences. Management will engage in a virtual fireside chat at Cowen's 3rd Annual Oncology Innovation Summit on June 2, 2022, at 12:30 p.m. ET. Additionally, they will partake in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference on June 14, 2022, at 6:20 p.m. ET in Rancho Palos Verdes, CA. Live webcasts of both events will be accessible on their website, along with a limited-time replay.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical firm focused on cancer therapies, announced CEO Michael A. Metzger's participation in a targeted oncology panel at Citi's Biopharma Virtual Co-Panel Day on May 18, 2022, at 1:30 p.m. ET. The event will highlight the company's innovative drug pipeline, including revumenib and axatilimab, which are currently in pivotal trials. A live webcast of the panel will be available on their website, along with a replay for limited access.
Syndax Pharmaceuticals (SNDX) reported its Q1 2022 financial results, revealing a net loss of $37.2 million or $0.63 per share, up from a loss of $27.7 million or $0.54 per share in Q1 2021. Research and development expenses rose to $30 million from $21.9 million due to increased clinical activities. The company is advancing its pivotal trials for revumenib (SNDX-5613) and axatilimab, with topline data expected in 1H23 and two FDA filings planned for 2023. As of March 31, 2022, Syndax had $397.9 million in cash and equivalents.
Syndax Pharmaceuticals (SNDX) will release its first quarter 2022 financial results on May 9, 2022, after U.S. market close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and business updates. Interested parties can access the webcast on the company's website. Syndax's pipeline includes promising cancer therapies such as SNDX-5613, a Menin–MLL inhibitor, axatilimab, a CSF-1 receptor blocker, and entinostat, a class I HDAC inhibitor.
Syndax Pharmaceuticals announced an inducement award for its new Chief Medical Officer, Dr. Catherine Madigan, granting her the option to purchase 180,000 shares of common stock at an exercise price of $16.06, equal to the closing stock price on March 1, 2022. This option will vest over four years, with a quarter vesting after one year and the remainder vesting monthly after that. The award, approved by Syndax's Board of Directors, complies with NASDAQ Listing Rule 5635(c)(4). Syndax is developing a pipeline of innovative cancer therapies including SNDX-5613 and axatilimab.
Syndax Pharmaceuticals reported strong fourth-quarter results for 2021. The company recorded a net profit of $96.2 million, or $1.81 per share, compared to a loss of $20.4 million in the same period last year. License revenue surged to $126.6 million due to a collaboration with Incyte. Syndax outlined significant progress in its clinical pipeline, expecting topline data from pivotal trials in 2023. Cash and equivalents stood at $439.9 million, providing ample runway for ongoing research and development.
Syndax Pharmaceuticals (SNDX) appointed Kate Madigan, M.D., as Chief Medical Officer, effective immediately. Dr. Madigan brings over 20 years of clinical hematology expertise and will lead the clinical development strategy at Syndax. She succeeds Michael Meyers, M.D., Ph.D., who will transition to a consulting role. Under her leadership, Syndax expects to advance its pipeline, which includes SNDX-5613 and axatilimab, with pivotal FDA filings anticipated next year, positioning the company to impact underserved cancer treatment areas.
Syndax Pharmaceuticals announced participation in two investor conferences: a panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET, and a presentation at the Barclays Global Healthcare Conference on March 16, 2022, at 3:50 p.m. ET. Both events will be available via live webcast on www.syndax.com, along with replays. Syndax is advancing an innovative cancer therapy pipeline, including SNDX-5613, axatilimab, and entinostat. These events aim to engage investors and communicate the company’s progress in developing cancer treatments.
Soligenix, a late-stage biopharmaceutical company focused on rare diseases, will present at the BIO CEO & Investor Conference from February 14-17, 2022. The presentation, available on-demand from February 11, will be led by CEO Christopher J. Schaber, PhD. Attendees can also schedule one-on-one meetings with management during the conference. Soligenix is advancing potential treatments like HyBryte™ for cutaneous T-cell lymphoma and RiVax® for ricin toxin exposure. For more details, visit the conference website.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
What does Syndax Pharmaceuticals, Inc. specialize in?
What are Syndax's key product candidates?
Where is Syndax Pharmaceuticals located?
What recent milestones has Syndax Pharmaceuticals achieved?
What is the significance of revumenib?
Has revumenib received any special designations?
How does Syndax Pharmaceuticals maintain its financial health?
What upcoming events is Syndax participating in?
Where can I find more information about Syndax's clinical trials?
How can I contact Syndax Pharmaceuticals?
